Interstitial Lung Disease Care: questions and answers

In detail

The assessment follows international guidelines that define interstitial lung disease as a large group of disorders causing lung scarring. Our pulmonologists, radiologists, and pathologists review high-resolution CT patterns such as usual interstitial pneumonia, non-specific interstitial pneumonia, and hypersensitivity pneumonitis patterns.

Occupational and environmental exposure history is taken in detail. Multidisciplinary discussion improves diagnostic accuracy and often avoids the need for surgical biopsy.

Progressive pulmonary fibrosis is identified when patients meet at least two of three criteria: worsening symptoms, physiological decline in forced vital capacity or diffusion capacity, and radiological progression on imaging within one year.

In detail

The most common symptoms of idiopathic pulmonary fibrosis are dyspnoea and cough. Dyspnoea is usually exertional and associated with walking up inclines or steps. The cough is typically described as dry and hacking, and may start with a tickle in the throat.

Inspiratory crackles are the hallmark feature, reported in more than 90 percent of patients. Finger clubbing occurs in 25 to 50 percent of patients.

Misdiagnosis and delays in diagnosis are common; in one study, interstitial lung disease was most often misdiagnosed as asthma, pneumonia, or bronchitis.

Delays in diagnosis have been reported from one year to as long as three years, with longer delays associated with increased risk of death. Early referral allows timely high-resolution CT and multidisciplinary discussion.

In detail

Acute exacerbation is defined as acute respiratory deterioration without an identifiable cause such as infection or heart failure. Patients with progressive disease are especially prone to acute exacerbation.

If oxygen saturation drops below 88 percent on a six-minute walk test or at rest, oxygen therapy should be started. A mechanical ventilator may be used to support breathing during severe exacerbations.

Antibiotics, corticosteroids, and other drugs may be prescribed by doctors to treat an acute exacerbation.

Consider urgent referral for forced vital capacity decline of 5 to 10 percent from baseline, worsening dyspnoea or exercise tolerance, new oxygen requirement or increased supplemental oxygen needs, and acute respiratory deterioration which may indicate acute exacerbation.

In detail

Guidelines recommend high-resolution CT for any patient with abnormal chest X-ray and clinical findings consistent with interstitial lung disease. HRCT findings are categorised as usual interstitial pneumonia, probable usual interstitial pneumonia, indeterminate, or alternative diagnosis.

A usual interstitial pneumonia or probable usual interstitial pneumonia pattern can support diagnosis after multidisciplinary discussion without biopsy when clinical features suggest high pre-test probability, specifically males over 60 with smoking history and absence of connective tissue disease or hypersensitivity pneumonitis features.

Tissue sampling is typically required only for indeterminate patterns. Serum biomarkers are not recommended for the sole purpose of distinguishing idiopathic pulmonary fibrosis from other interstitial lung diseases. Transbronchial lung cryobiopsy is an acceptable alternative to surgical lung biopsy in centres with appropriate expertise. Pulmonary function tests are integral to monitoring progression and staging disease severity.

In detail

Multidisciplinary discussion integrates clinical, radiological, and pathological data to reach a consensus diagnosis. This changes management because idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, connective tissue disease related interstitial lung disease, and pneumoconiosis have different treatments.

Antifibrotic therapy with nintedanib or pirfenidone is indicated for idiopathic pulmonary fibrosis, systemic sclerosis associated interstitial lung disease, and progressive pulmonary fibrosis. These drugs slow forced vital capacity decline but require monitoring for liver toxicity and gastrointestinal side effects.

Immunosuppression is used for connective tissue disease related interstitial lung disease and some hypersensitivity pneumonitis cases. Antigen avoidance is critical for hypersensitivity pneumonitis. Pulmonary rehabilitation improves exercise capacity, dyspnoea, and quality of life and should begin early. Oxygen therapy is assessed by six-minute walk test.

Lung transplant referral criteria include forced vital capacity below 80 percent predicted, diffusion capacity below 40 percent, significant forced vital capacity decline, oxygen desaturation below 88 percent on six-minute walk test, and honeycombing on high-resolution CT.

In detail

Antifibrotics slow forced vital capacity decline in IPF and progressive fibrosing ILDs. Nintedanib reduces annual FVC decline by approximately 125 ml compared to placebo. Pirfenidone shows similar benefit in two of three phase 3 trials. For progressive pulmonary fibrosis, nintedanib has a conditional recommendation.

Immunosuppression is used for inflammatory phenotypes like hypersensitivity pneumonitis or connective tissue disease-related ILD. The combination of prednisone, azathioprine, and N-acetylcysteine is not recommended for IPF due to increased death and hospitalisation. Pulmonary rehabilitation improves exercise capacity, dyspnoea, and quality of life.

Oxygen is prescribed if saturation drops below 88 percent on a six-minute walk test. Acute exacerbations require hospitalisation, oxygen, antibiotics, and corticosteroids. Transplant referral is advised early for high-risk patients.

In detail

Antifibrotic therapy with nintedanib or pirfenidone slows forced vital capacity decline in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Nintedanib reduced the annual rate of decline by approximately 50 percent in trials. Pirfenidone showed benefit in two of three phase 3 trials.

Both require monitoring for liver toxicity and gastrointestinal side effects. Pulmonary rehabilitation is beneficial for interstitial lung disease including idiopathic pulmonary fibrosis, with short-term improvements in exercise capacity, dyspnoea, and quality of life. Patients derive the most benefit early in the disease course.

Oxygen therapy is indicated when saturation drops below 88 percent on six-minute walk test. Smoking cessation is critical as smoking is a risk factor. Antigen avoidance is the cornerstone of hypersensitivity pneumonitis management. Vaccinations against influenza and pneumococcus are recommended.

Antacid medications should not be prescribed for the purpose of improving idiopathic pulmonary fibrosis respiratory outcomes. Antireflux surgery should not be performed for idiopathic pulmonary fibrosis respiratory outcomes. Observation with regular follow-up may suit stable, non-progressive disease.

• Nintedanib reduced the annual rate of decline by approximately 50 percent in trials.

In detail

Guidelines strongly recommend against surgical lung biopsy, transbronchial lung biopsy, and lung cryobiopsy when high-resolution CT shows a usual interstitial pneumonia pattern. For probable usual interstitial pneumonia, indeterminate, or alternative diagnosis patterns, conditional recommendations support bronchoalveolar lavage and surgical lung biopsy after multidisciplinary discussion.

Transbronchial lung cryobiopsy is an acceptable alternative to surgical lung biopsy in centres with appropriate expertise. Surgical lung biopsy by video-assisted thoracoscopic surgery requires general anaesthesia and a hospital stay of 2 to 3 days.

Lung transplant referral criteria include forced vital capacity below 80 percent predicted, diffusion capacity below 40 percent predicted, significant forced vital capacity decline of 5 percent or more over 6 months, oxygen desaturation below 88 percent on six-minute walk test, and honeycombing on high-resolution CT.

Patients at increased risk of mortality should be referred for transplant evaluation at the time of diagnosis, not delayed until moderate-to-severe disease.

In detail

In studies, nintedanib reduced the annual rate of decline in forced vital capacity by about 125 ml compared with placebo, and pirfenidone showed a similar slowing of disease progression in two of three phase 3 trials.

These medicines do not reverse fibrosis that is already present. The multidisciplinary team at Jaipur Hospital uses serial pulmonary function tests and HRCT scans every three to six months to confirm that the rate of decline has slowed. Improvement in symptoms such as cough or exertional dyspnoea is not the primary goal; stabilisation is.

In detail

Evidence shows that ILD patients, especially those with progressive disease, are prone to acute exacerbation leading to frequent hospitalisations. The combination of prednisone, azathioprine, and N-acetylcysteine was associated with increased death and hospitalisation in IPF and is not recommended.

At Jaipur Hospital, the team will check for infection, pulmonary embolism, or heart failure as treatable causes. They may adjust antifibrotic dose, start supplemental oxygen, or admit you for intravenous steroids and supportive care. Early reporting of worsening symptoms allows faster intervention and better outcomes.

In detail

Pulmonary rehabilitation is beneficial for ILD and is associated with short-term improvements in exercise capacity, dyspnoea, and quality of life. Starting rehab early after diagnosis gives the most benefit.

Antifibrotics such as nintedanib commonly cause diarrhoea, which may affect workplace comfort and travel plans; dose adjustment or loperamide can help. Oxygen desaturation below 88 percent on exertion indicates a need for portable oxygen during flights or long journeys. The multidisciplinary team will evaluate fitness for specific job demands and issue fitness certificates as required.

In detail

Guidelines recommend assessing the need for oxygen therapy with a six-minute walk study. If saturation drops below 88 percent, an oxygen titration component determines the flow rate needed to maintain saturations above 88 percent with exertion.

Airlines require medical information forms (MEDIF) submitted 48 to 72 hours before flight, but the testing and paperwork take longer. For workplace fitness, the team evaluates exertional desaturation, dyspnoea score, and job demands. Early referral for transplant evaluation is also advised at diagnosis if criteria are met, not delayed until severe disease.

In detail

Patients with ILD are at increased risk for pulmonary infection, so vaccination is a key preventive measure. The 2022 guidelines do not recommend antacid therapy or antireflux surgery for IPF respiratory benefit, but GERD treatment may be given for symptom control.

For air travel, airlines require a Medical Information Form (MEDIF) completed by your pulmonologist. For workplace fitness, a certificate detailing functional capacity, oxygen needs, and any restrictions is issued after clinical assessment. All records should be in English or Hindi for easy verification.

In detail

Antifibrotics are taken daily without interruption. Nintedanib is usually taken twice daily with food to reduce gastrointestinal upset; pirfenidone is taken three times daily with food and requires gradual dose escalation over two weeks. Missing doses reduces the slowing effect on lung function decline.

Carry enough supply for the entire trip plus one week extra. In India, these medicines are available at hospital pharmacies and major chemists with a valid prescription.

Liver function tests are monitored every month for the first three months and then every three months; plan blood tests around travel dates.

In detail

Guidelines list coronary artery disease, lung cancer, obstructive sleep apnoea, emphysema, pulmonary hypertension, pulmonary infection, gastro-oesophageal reflux, hiatal hernia, and diabetes as frequent comorbidities in IPF. Each adds risk during flight hypoxia or exertion.

A six-minute walk test with oxygen saturation monitoring is the standard way to assess fitness for flying. For work, the team reviews job demands, exertional desaturation, dyspnoea score, and need for supplemental oxygen.

Antifibrotic side effects such as diarrhoea or liver enzyme rise may also influence shift work or remote-site rotations. Fitness certificates are issued only after this comprehensive review.

In detail

Patients with ILD are prone to acute exacerbation triggered by infection, aspiration, or environmental exposure. Occupational antigens such as silica, bird proteins, or moulds can drive hypersensitivity pneumonitis progression.

The 2022 guidelines define progressive pulmonary fibrosis by worsening symptoms, physiological decline (FVC drop of 5 percent or more, or DLCO drop of 10 percent or more), and radiological progression within a year. Heat and dehydration thicken secretions and increase breathlessness.

Long immobilisation raises venous thromboembolism risk. The team advises compression stockings, hydration, and prescribed oxygen flow rates for flights. Workplace modifications may include dust extraction, respirators, or role change.

In detail

Interstitial lung disease can worsen quickly, especially if an infection or acute exacerbation develops. Evidence shows that acute exacerbations lead to frequent hospitalisations and need prompt assessment.

Having your HRCT images, pulmonary function test reports, and a list of antifibrotic drugs such as nintedanib or pirfenidone helps the attending doctor avoid treatments that may be harmful, such as high-dose steroids without a clear indication. Your surgeon or pulmonologist at Jaipur Hospital can then review the local findings and adjust your plan.

In detail

Guidelines recommend HRCT as the radiographic standard for ILD diagnosis. The HRCT pattern is categorised as UIP, probable UIP, indeterminate, or an alternative diagnosis.

A UIP pattern on HRCT can support a diagnosis of idiopathic pulmonary fibrosis after multidisciplinary discussion without biopsy when clinical features fit. For probable UIP, indeterminate, or alternative patterns, conditional recommendations exist for further tests such as bronchoalveolar lavage or surgical lung biopsy.

Early and accurate classification avoids delays; studies show misdiagnosis is common and delays of one to three years are linked to higher mortality.

In detail

Antifibrotic therapy should be initiated promptly at diagnosis because IPF is irreversibly progressive from that moment.

Evidence from phase 3 trials shows nintedanib reduces the annual rate of FVC decline by about 125 millilitres compared with placebo, and pirfenidone reduces disease progression in two of three trials.

Both drugs require ongoing monitoring for liver function and gastrointestinal side effects such as diarrhoea, which leads to discontinuation in less than five percent of patients on nintedanib. Combination therapy with prednisone, azathioprine, and N-acetylcysteine is associated with increased death and hospitalisation and is not recommended.

In detail

Connective tissue disease-associated ILD often shows a nonspecific interstitial pneumonia (NSIP) pattern on HRCT, but a usual interstitial pneumonia (UIP) pattern can also occur. Guidelines recommend serologic testing for most patients with suspected ILD to exclude underlying connective tissue disease.

The index of suspicion should be high for women younger than 60 years. Features such as extensive honeycombing occupying more than 70 percent of fibrotic lung, a straight-edge sign on coronal images, or anterior upper lobe predominance suggest connective tissue disease-related UIP. Early diagnosis allows timely immunosuppression or antifibrotic therapy depending on the pattern and progression.

In detail

HRCT features that suggest fibrotic hypersensitivity pneumonitis include upper or mid-lung predominance of fibrosis and honeycombing, mosaic attenuation, or a three-density sign. These patterns differ from the basal predominance typical of idiopathic pulmonary fibrosis. Identifying and removing the triggering antigen is the cornerstone of management.

In fibrotic HP that progresses despite antigen avoidance, antifibrotic therapy with nintedanib may be considered, as progressive pulmonary fibrosis criteria apply. Misdiagnosis as IPF can lead to missed opportunities for antigen avoidance and inappropriate therapy.

In detail

Acute exacerbations of interstitial lung disease are life-threatening events defined by acute respiratory deterioration, new ground-glass opacities on imaging, and no identifiable cause such as infection or heart failure. Evidence shows they lead to frequent hospitalisations and high mortality.

Guidelines recommend assessing oxygen need with a six-minute walk test; if saturation drops below 88 percent, oxygen titration is required. Acute exacerbations are treated with high-dose corticosteroids, antibiotics, and supportive care including mechanical ventilation if needed. Prompt recognition and hospital admission improve outcomes.

In detail

Evidence shows that cigarette smoking is a major risk factor for idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema. Occupational exposures to silica, asbestos, metal dusts, and organic antigens cause specific ILDs such as asbestosis, silicosis, and hypersensitivity pneumonitis.

Air pollution is increasingly recognised as a risk factor for progressive fibrosis. Comorbidities are common: studies report coronary artery disease, lung cancer, obstructive sleep apnoea, emphysema, pulmonary hypertension, infection, GERD, hiatal hernia, and diabetes mellitus occur more frequently in IPF patients.

Addressing these factors — smoking cessation, antigen avoidance, reflux management, and treating sleep apnoea — can slow progression and improve quality of life.

In detail

Costs vary by disease severity, comorbidities, and treatment choice. Evidence shows inpatient care accounts for 40 to 89 percent of total direct costs globally, while medication costs contribute 18 to 82 percent.

Antifibrotic therapy is a major recurring expense; studies comparing nintedanib and pirfenidone find either may be cost-effective depending on local pricing and health system thresholds. Jaipur Hospital accepts RGHS, MAA Yojana, CGHS, and private insurance panels, which can reduce out-of-pocket expenditure. The multidisciplinary approach aims to avoid unnecessary tests and hospitalisations, which are the largest cost drivers.

In detail

Our usual protocols show a consultation range of ₹2,000 to ₹6,000 and an HRCT plus PFT package range of ₹15,000 to ₹30,000. Antifibrotic therapy with nintedanib or pirfenidone typically costs ₹50,000 to ₹1,50,000 per month.

If the multidisciplinary discussion cannot reach a confident diagnosis, a VATS surgical biopsy may be advised; its typical range in India is ₹1,50,000 to ₹3,00,000 and includes a two to three day hospital stay.

Evidence indicates that inpatient care, medication, and outpatient visits are the main cost drivers in interstitial lung disease management, so each component is itemised.